When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Asthma in adults

Last reviewed: 21 Nov 2024
Last updated: 24 Oct 2024
01 Aug 2024

GINA reiterates montelukast safety warning

​The 2024 GINA guideline update reminds prescribers of the potential risk of neuropsychiatric adverse events in patients receiving montelukast, including:[52]

  • new-onset nightmares,

  • behavioral and mood problems (e.g., agitation, hyperactivity, irritability, nervousness, aggression), and

  • suicidal ideation.

Healthcare professionals should consider the benefits and risks before prescribing montelukast and have an open discussion with patients about potential adverse effects.

Healthcare professionals and patients should be alert to, and monitor for, serious behavior and mood-related changes during treatment.

See Management: approach

Original source of update

Summary

Definition

History and exam

Key diagnostic factors

  • recent upper respiratory tract infection
  • dyspnea
  • cough
  • expiratory wheezes
  • nasal polyposis
Full details

Risk factors

  • family history
  • allergens/irritants
  • atopic disease history
  • cigarette smoking
  • vaping
  • respiratory viral infection early in life
  • nasal polyposis
  • low socioeconomic status
  • obesity
  • gastroesophageal reflux
  • obstructive sleep apnea
Full details

Diagnostic tests

1st tests to order

  • FEV₁/FVC ratio
  • peak expiratory flow (PEF)
Full details

Tests to consider

  • chest x-ray
  • CBC
  • fractional exhaled nitric oxide (FeNO)
  • bronchial challenge test
  • immunoassay for allergen-specific IgE
  • skin prick allergy testing
  • high-resolution CT (HRCT) chest
  • CT sinus
Full details

Emerging tests

  • sputum eosinophil count

Treatment algorithm

ACUTE

initial treatment step 1: asthma symptoms 1-2 days per week or less and no risk factors for exacerbations

initial treatment step 2: asthma symptoms less than 3-5 days per week and normal (or mildly reduced) lung function

initial treatment step 3: asthma symptoms most days (e.g., 4-5 days per week or more), or waking due to asthma once a week or more, low lung function, and risk factors for exacerbations

initial treatment step 4: daily asthma symptoms, waking at night once a week or more, and low lung function

ONGOING

ongoing treatment step 1: patients using short-acting beta agonist (SABA) alone or with newly diagnosed asthma, with normal (or mildly reduced) lung function

ongoing treatment step 2: asthma not controlled on step 1 treatment

ongoing treatment step 3: asthma not controlled on steps 1-2 treatment (track 1) or step 2 treatment (track 2), with risk factors for exacerbations

ongoing treatment step 4: asthma not controlled on step 3 treatment

ongoing treatment step 5: asthma not controlled on step 4 treatment and patient reviewed by specialist

Contributors

Authors

Lauren E. Eggert, MD

Clinical Assistant Professor

Division of Pulmonary, Allergy, and Critical Care Medicine

Department of Medicine

Stanford University School of Medicine

Stanford

CA

Disclosures

LEE has participated on advisory boards for Regeneron and AstraZeneca.

Sourav Majumdar, MD

Clinical Assistant Professor (Affiliated)

Division of Pulmonary and Critical Care Medicine

Department of Medicine

Stanford University School of Medicine

Stanford

CA

Disclosures

SM declares that he has no competing interests.

Acknowledgements

Dr Lauren E. Eggert and Dr Sourav Majumdar would like to gratefully acknowledge Dr Irwani Ibrahim, Dr Kay Choong See, Dr Francis Thien, and Dr Catherine Weiler, previous contributors to this topic.

Disclosures

II, KCS, FT, and CW declare that they have no competing interests.

Peer reviewers

Javed Sheikh, MD

Clinical Director

Division of Allergy and Inflammation

Beth Israel Deaconess Medical Center/Harvard Medical School

Boston

MA

Disclosures

JS is a consultant for Aventis, GSK, and Novartis/Genentech; is on the Speakers Bureau for Merck, Aventis, GSK, AstraZeneca, Pfizer, Novartis/Genentech, Inspire, and UCB; has had research sponsored by GSK; is an expert witness at Haemonetics; and has received publication honorarium at Emedicine.

Sheree M.S. Smith, PhD

Research Manager

Imperial College Healthcare Trust

NHLI Airways Division

Imperial College London (Honorary) Respiratory Research

Chest & Allergy

St Mary's Hospital

London

UK

Disclosures

SMSS declares that she has no competing interests.

Neil Thomson, MBChB, MD, FRCP

Professor of Respiratory Medicine

Respiratory Medicine Section

Division of Immunology, Infection & Inflammation

University of Glasgow

Glasgow

UK

Disclosures

NT declares that he has no competing interests.

  • Differentials

    • Cystic fibrosis
    • Chronic rhinosinusitis
    • Tracheomalacia
    More Differentials
  • Guidelines

    • Global strategy for asthma management and prevention
    • 2020 focused updates to the asthma management guidelines
    More Guidelines
  • Patient information

    Asthma in adults: what is it?

    Asthma in adults: what treatments work?

    More Patient information
  • Videos

    Polyphonic wheeze

    Expiratory wheeze

    More videos
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer